Antidepressants to Procure 48% Market Share for Generalized Anxiety Disorder Treatment Market | FMI Study

During the forecast period 2023 to 2033, the Generalized anxiety disorder treatment market is expected to grow at a value of 9% CAGR, according to Future Market Insights. By the year 2033, the global market for Generalized anxiety disorder treatment market is expected to rise up to a market valuation of US$ 4261.25 Million.

Growth of the market can be attributed to increasing prevalence and awareness of mental health issues. In addition, research and development to offer therapeutic treatments along with better antidepressants are boosting the growth of the market.

The most common treatment options for GAD include medications such as antidepressants, benzodiazepines, and beta-blockers, as well as psychotherapy such as cognitive-behavioral therapy (CBT) and mindfulness-based therapy. The demand for these treatments is expected to increase as more people seek help for their GAD symptoms.

Get a Sample of this Research Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16745

The Generalized Anxiety Disorder Treatment Market is also expected to benefit from the growing use of digital technologies such as telemedicine and mobile health apps. These technologies can help to increase access to treatment for people who may not have easy access to mental health services.

Key Takeaways from the Market Study

• The generalized anxiety disorder treatment market is expected to grow at a value of 9% CAGR in the forecast period 2023 to 2033.
• By drug class, antidepressants are expected to possess 48% market share for generalized anxiety disorder treatment market in 2023.
• North America is expected to possess 47% market share for generalized anxiety disorder treatment market in 2023.
• Asia Pacific is expected to possess 42% market share for generalized anxiety disorder treatment market in 2023.

“The market for psychotherapy is expected to grow, driven by the increasing awareness of the importance of mental health and the growing availability of online therapy services.” states an FMI analyst

Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16745

Competitive Landscape

Key players in the generalized anxiety disorder treatment market are MindMed, VistaGen Therapeutics, Actavis, Takeda Pharmaceuticals, Bionomics, Eli Lilly and Company, GlaxoSmithKline Pharmaceuticals Limited, Pfizer, Inc., Abbott Laboratories, Bristol-Myers Squibb and Actavis Pharmaceutical Company

• MindMed has developed a digital therapeutics platform called “Lytica” that aims to improve mental health outcomes for patients with anxiety disorders. The platform uses cognitive-behavioral therapy (CBT) techniques to help patients manage their symptoms and improve their mental well-being.
• Actavis offers a number of drugs that are commonly used in the treatment of GAD, including benzodiazepines like clonazepam and lorazepam. These drugs work by enhancing the activity of gamma-aminobutyric acid (GABA), a neurotransmitter that has a calming effect on the brain.

More Valuable Insights

Future Market Insights, in its new offering, presents an unbiased analysis of the global Generalized anxiety disorder treatment market market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.

The study reveals essential insights on the basis of Drug Class (Antidepressant, Buspirone, Benzodiazepines) Therapies (Interpersonal Therapy, Behavioural Therapy, Cognitive Behaviour Therapy, Mindfulness Based Cognitive Therapy) Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Region (North America, Latin America, Europe, South Asia, East Asia, Oceania, MEA)

Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16745

Key Segments Profiled in the Generalized Anxiety Disorder Treatment Industry Survey

Drug Class:

• Antidepressant
• Buspirone
• Benzodiazepines

Therapies:

• Interpersonal Therapy
• Behavioural Therapy
• Cognitive Behaviour Therapy
• Mindfulness Based Cognitive Therapy

Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs